GLP-3 RT – Retatrutide (20MG)

Description

GLP-3 RT is a synthetic peptide designed for in vitro research applications involving GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon receptor pathways. As a triple receptor agonist, it represents a structurally distinct research tool compared to dual or single-agonist analogues currently documented in the scientific literature.

Molecular Profile
Format: Lyophilized white powder
Storage: -20°C, desiccated
Reconstitution: Sterile bacteriostatic water

Molecular formula:

C162H261N43O51
Purity: 99%+

Certificate of Analysis

View COA (PDF) : PTC-2PGJMS4N

Sequence:

H-Aib-Glu-Glu-Glu-Glu-Glu-Aib-Ser-Gln-Tyr-Leu-Leu-Lys-Asp-Phe-Arg-Leu-Gln-Aib-Leu-Ser-Gln-Ala-Gln-Aib-Leu-Ser

Research Context
GLP-3 RT’s triple receptor profile has generated significant interest in metabolic signaling research. Peer-reviewed preclinical literature documents its utility in studying simultaneous activation of GIP, GLP-1, and glucagon receptor pathways, including downstream effects on adipose tissue biology, hepatic glucose output, and energy expenditure regulation. Research teams investigating incretin-based signaling cascades use triple agonist compounds to isolate receptor-specific contributions to metabolic outcomes.

This compound is available exclusively for in vitro laboratory research and scientific study conducted within Canada. It is not a drug, natural health product, or food product as defined under the Food and Drugs Act (R.S.C., 1985, c. F-27). It is not approved for human consumption, veterinary use, or any diagnostic or therapeutic application. This product has not been evaluated by Health Canada. Researchers are responsible for compliance with all applicable federal, provincial, and local regulations.